Bipolar Disorder

What it is

Bipolar disorder is a mood disorder defined not by sadness but by instability — recurring episodes of elevated, energized mood (mania or hypomania) that, in most people, alternate with episodes of depression. The defining feature, the one that sets it apart from depression, is the presence at some point of an abnormally high or irritable, high-energy state. Understanding bipolar disorder as a disorder of mood and energy regulation — a system that swings too far in both directions and struggles to stay level — is more accurate than the popular image of simple "mood swings," which happen on a timescale of minutes and are a different phenomenon entirely.

The two poles look very different. Mania is a sustained period (at least a week, or any duration if it requires hospitalization) of abnormally elevated, expansive, or irritable mood together with markedly increased energy or activity, plus several of the following: inflated self-esteem or grandiosity, a sharply reduced need for sleep (feeling rested after very little), pressured speech, racing thoughts, distractibility, a surge in goal-directed activity or agitation, and impulsive, risky behavior such as reckless spending, sexual indiscretion, or dangerous ventures. Mania causes serious impairment and can include psychosis. Hypomania is a milder, shorter version (at least four days) — a noticeable change in functioning observable to others, but without the severe impairment or psychosis of mania. Depressive episodes resemble those of major depression, and — importantly — most people with bipolar disorder spend far more time depressed than elevated.

Subtypes and specifiers

Bipolar disorder is not one thing. Bipolar I is defined by at least one full manic episode (depressive episodes usually occur but are not strictly required). Bipolar II is defined by at least one hypomanic episode plus at least one major depressive episode, with no full mania — and it is a common error to think of it as "mild," since the depressive burden is often heavy and disabling. Cyclothymia is a chronic, lower-grade instability with subthreshold highs and lows lasting two years or more.

Specifiers add important detail: mixed features (manic and depressive symptoms at once — a high-risk state closely tied to the irritability and agitation that complicate treatment), rapid cycling (four or more episodes a year), psychotic features, and seasonal or peripartum patterns. Many clinicians also think in terms of a broader bipolar spectrum — a view, developed influentially by Ghaemi and others, that softer, harder-to-classify presentations sit between clear bipolar disorder and unipolar depression, a concept central to the ongoing debate about how often bipolarity is missed.

How common, and who

Bipolar I affects roughly 1% of the population and bipolar II about another 1%, with broader spectrum presentations pushing estimates higher. Bipolar I occurs about equally in men and women. Onset is typically in adolescence or early adulthood — earlier, on average, than unipolar depression — and one of the field's persistent problems is the long delay, often years, between first symptoms and correct diagnosis, because people usually present while depressed and the earlier highs go unrecognized or unreported.

What causes it

Bipolar disorder has the highest heritability of the major psychiatric disorders — twin studies suggest genetic factors account for a large majority of risk — and it is, like depression, highly polygenic. Its biology points toward mood and circadian instability, with disrupted sleep-wake rhythms playing a central and clinically important role; toward mitochondrial and cellular-energy disturbances; toward ion-channel genetics (calcium-channel genes feature prominently); and toward dopamine dysregulation in the manic state. The concept of "kindling" — episodes becoming more autonomous and easily triggered over time — captures the tendency of untreated bipolar disorder to worsen, and underlies the emphasis on early, sustained treatment.

How it is diagnosed

Diagnosis is clinical, and the central challenge — arguably the most consequential differential in mood disorders — is distinguishing bipolar disorder from unipolar depression. Because most people seek help during a depressive episode, and because hypomania can feel good or simply productive rather than like a problem to report, the bipolar diagnosis is frequently missed for years and treated as ordinary depression. Screening every depressed patient for any past period of elevated, energized, reduced-sleep states is therefore essential; tools like the Mood Disorder Questionnaire assist, but careful history is key.

Several features raise suspicion of bipolarity in someone presenting with depression: an early age of onset, a strong family history, postpartum onset, psychotic or atypical features, highly recurrent or brief episodes, and a history of becoming manic, agitated, or irritable on antidepressants. The differential also includes borderline personality disorder (which involves rapid, trigger-linked mood shifts on a different timescale), ADHD (with which it shares distractibility, energy, and impulsivity, especially in young people), schizophrenia and schizoaffective disorder, and substance-induced or medical mood changes. Misdiagnosis runs in both directions and matters greatly.

Why the distinction matters

Course and prognosis

Bipolar disorder is chronic and recurrent, typically lifelong, with a strong tendency to relapse if untreated. It carries substantial disability, and cognitive and functional difficulties can persist even between episodes. It also carries one of the highest suicide risks of any psychiatric condition, far above the general population, which makes safety a continuous priority. Comorbidity — anxiety disorders, substance use — is common and worsens outcomes. Yet the prognosis is far from uniformly bleak: with consistent treatment, many people achieve long periods of stability and full, productive lives, and recognizing the condition is itself the turning point for many.

Treatment

Treatment aims to resolve acute episodes, prevent both poles from recurring, and stabilize the underlying rhythm of mood and sleep.

Mood stabilizers are the backbone. Lithium remains the gold standard — effective against mania, protective against relapse, and, uniquely among psychiatric treatments, associated with reduced suicide risk — though it requires monitoring and is, notably, under-used relative to its evidence. Valproate, lamotrigine (particularly valuable for the depressive pole and for maintenance), and carbamazepine are other options.

Antipsychotics treat acute mania and, increasingly, bipolar depression: several agents (quetiapine, lurasidone, cariprazine, lumateperone, and an olanzapine-fluoxetine combination) are used for the depressive phase. For bipolar depression specifically, the rational approach uses these agents and mood stabilizers rather than antidepressant monotherapy. Acute mania is treated with an antipsychotic, often combined with lithium or valproate, with ECT reserved for severe or refractory mania and for mixed states.

Psychosocial treatment is not optional add-on but core: psychoeducation (which markedly improves outcomes), family-focused therapy, interpersonal and social rhythm therapy (which stabilizes daily routines and sleep-wake timing), and CBT. Because sleep loss can trigger mania, regularizing sleep and daily rhythm — and avoiding substances — is one of the most powerful and practical interventions available.

Controversies and honest caveats

Several debates run through the field. The over- versus under-diagnosis argument is genuine: spectrum advocates contend that bipolarity is frequently missed and mistreated as unipolar depression, while skeptics worry that loose criteria lead to over-diagnosis — and both can be true in different settings. The role of antidepressants in bipolar disorder remains contested, with most authorities urging caution and reserving them for adjunctive, carefully monitored use. Bipolar II is too often dismissed as mild, when its depressive burden and suicide risk are substantial. Distinguishing it from borderline personality disorder is frequently difficult and consequential. And lithium's under-use — despite being the best-evidenced mood stabilizer and the one agent linked to lower suicide risk — reflects a gap between evidence and practice that many experts consider a genuine failing.

Bottom line

Bipolar disorder is a highly heritable, lifelong disorder of mood and energy regulation, defined by episodes of mania or hypomania that usually alternate with depression, and best understood as a failure of the system that keeps mood and rhythm level. Its central clinical danger is being mistaken for ordinary depression — a mistake that delays effective care for years and can be made worse by antidepressants given without a mood stabilizer. It carries serious risks, including one of the highest suicide rates in psychiatry, but it is also genuinely treatable: lithium and other mood stabilizers, antipsychotics for the depressive and manic poles, and rhythm-stabilizing psychosocial treatment allow many people to achieve lasting stability. The keys are recognizing it, protecting sleep and routine, building the right medication foundation, and treating it as the chronic, manageable condition it is.

Selected references

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5-TR). 2022.
2. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016.
3. Vieta E, et al. Bipolar disorders. Nat Rev Dis Primers. 2018.
4. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013.
5. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. 2007.
6. Merikangas KR, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011.
7. Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011.
8. Cipriani A, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013.
9. BALANCE investigators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE). Lancet. 2010.
10. McIntyre RS, et al. Bipolar disorders. Lancet. 2020.
11. Yatham LN, et al. CANMAT and ISBD guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018.
12. Miklowitz DJ, et al. Psychosocial treatments for bipolar depression: a randomized controlled trial. Arch Gen Psychiatry. 2007.
13. Frank E, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005.
14. Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord. 2008.
15. Colom F, et al. Group psychoeducation for stabilized bipolar disorders: 5-year outcome. Br J Psychiatry. 2009.
16. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013.
17. Ghaemi SN. Mood Disorders: A Practical Guide. (Spectrum and mood-stabilizer perspectives.)
18. Tondo L, Vázquez GH, Baldessarini RJ. Depression and mania in bipolar disorder. Curr Neuropharmacol. 2017.